Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy

Maha S Al-Keilani,1 Dua H Alsmadi,1 Ruba S Darweesh,2 Karem H Alzoubi1 1Department of Clinical Pharmacy, College of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan; 2Department of Pharmaceutical Technology, College of Pharmacy, Jordan University of Science and Technology, Irbid,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Al-Keilani MS, Alsmadi DH, Darweesh RS, Alzoubi KH
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	colorectal cancer resistance amylin analog pramlintide adjuvant chemotherapy synergism Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/cb3da58ca5024fc889a488017fdcef9e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cb3da58ca5024fc889a488017fdcef9e
record_format	dspace
spelling	oai:doaj.org-article:cb3da58ca5024fc889a488017fdcef9e2021-12-02T01:17:57ZPramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy1179-1438https://doaj.org/article/cb3da58ca5024fc889a488017fdcef9e2018-03-01T00:00:00Zhttps://www.dovepress.com/pramlintide-an-antidiabetic-is-antineoplastic-in-colorectal-cancer-and-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Maha S Al-Keilani,1 Dua H Alsmadi,1 Ruba S Darweesh,2 Karem H Alzoubi1 1Department of Clinical Pharmacy, College of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan; 2Department of Pharmaceutical Technology, College of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan Background: Approximately 90% of patients with metastatic colorectal cancer fail therapy mainly due to resistance. Taking advantage of currently approved agents for treatment of disease conditions other than cancer for the identification of new adjuvant anticancer therapies is highly encouraged. Pramlintide is a parenteral antidiabetic agent that is currently approved for treatment of types 1 and 2 diabetes mellitus.Objectives: To address the antineoplastic potential of pramlintide in colorectal cancer and to evaluate the ability of pramlintide to enhance the cytotoxicity of 5-fluorouracil, oxaliplatin, and irinotecan against colorectal cancer cell lines expressing wild-type and mutant p53.Materials and methods: The antiproliferative effect of pramlintide alone or in combination with 5-fluorouracil, oxaliplatin, or irinotecan in HCT-116 and HT-29 colorectal cancer cell lines was investigated using MTT cell proliferation assay. IC50 values were calculated using Compusyn software 1.0. Synergy values (R) were calculated using the ratio of IC50 of each primary drug alone divided by combination IC50s. For each two pairs of experiments, Student’s t-test was used for analysis. For combination studies, one-way analysis of variance and Tukey post hoc testing was performed using R 3.3.2 software. A p-value of <0.05 was considered significant.Results: Pramlintide inhibited the growth of HCT-116 and HT-29 in a dose-dependent manner, with higher efficacy against the latter (IC50s; 48.67 and 9.10 µg/mL, respectively; p-value =0.013). Moreover, the addition of 5, 10, and 20 µg/mL of pramlintide to HCT-116 and HT-29 with 5-fluorouracil, oxaliplatin, or irinotecan induced the antiproliferative effect synergistically (R>1.6, p-value <0.05).Conclusion: Pramlintide enhances the cytotoxicity of conventional chemotherapy against colorectal cancer cell lines harboring wild-type or mutant p53. Thus, pramlintide is a promising potential adjuvant chemotherapy in colorectal cancer. Keywords: colorectal cancer, resistance, amylin analog, pramlintide, adjuvant chemotherapy, synergismAl-Keilani MSAlsmadi DHDarweesh RSAlzoubi KHDove Medical Pressarticlecolorectal cancerresistanceamylin analogpramlintideadjuvant chemotherapysynergismTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 10, Pp 23-29 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	colorectal cancer resistance amylin analog pramlintide adjuvant chemotherapy synergism Therapeutics. Pharmacology RM1-950
spellingShingle	colorectal cancer resistance amylin analog pramlintide adjuvant chemotherapy synergism Therapeutics. Pharmacology RM1-950 Al-Keilani MS Alsmadi DH Darweesh RS Alzoubi KH Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy
description	Maha S Al-Keilani,1 Dua H Alsmadi,1 Ruba S Darweesh,2 Karem H Alzoubi1 1Department of Clinical Pharmacy, College of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan; 2Department of Pharmaceutical Technology, College of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan Background: Approximately 90% of patients with metastatic colorectal cancer fail therapy mainly due to resistance. Taking advantage of currently approved agents for treatment of disease conditions other than cancer for the identification of new adjuvant anticancer therapies is highly encouraged. Pramlintide is a parenteral antidiabetic agent that is currently approved for treatment of types 1 and 2 diabetes mellitus.Objectives: To address the antineoplastic potential of pramlintide in colorectal cancer and to evaluate the ability of pramlintide to enhance the cytotoxicity of 5-fluorouracil, oxaliplatin, and irinotecan against colorectal cancer cell lines expressing wild-type and mutant p53.Materials and methods: The antiproliferative effect of pramlintide alone or in combination with 5-fluorouracil, oxaliplatin, or irinotecan in HCT-116 and HT-29 colorectal cancer cell lines was investigated using MTT cell proliferation assay. IC50 values were calculated using Compusyn software 1.0. Synergy values (R) were calculated using the ratio of IC50 of each primary drug alone divided by combination IC50s. For each two pairs of experiments, Student’s t-test was used for analysis. For combination studies, one-way analysis of variance and Tukey post hoc testing was performed using R 3.3.2 software. A p-value of <0.05 was considered significant.Results: Pramlintide inhibited the growth of HCT-116 and HT-29 in a dose-dependent manner, with higher efficacy against the latter (IC50s; 48.67 and 9.10 µg/mL, respectively; p-value =0.013). Moreover, the addition of 5, 10, and 20 µg/mL of pramlintide to HCT-116 and HT-29 with 5-fluorouracil, oxaliplatin, or irinotecan induced the antiproliferative effect synergistically (R>1.6, p-value <0.05).Conclusion: Pramlintide enhances the cytotoxicity of conventional chemotherapy against colorectal cancer cell lines harboring wild-type or mutant p53. Thus, pramlintide is a promising potential adjuvant chemotherapy in colorectal cancer. Keywords: colorectal cancer, resistance, amylin analog, pramlintide, adjuvant chemotherapy, synergism
format	article
author	Al-Keilani MS Alsmadi DH Darweesh RS Alzoubi KH
author_facet	Al-Keilani MS Alsmadi DH Darweesh RS Alzoubi KH
author_sort	Al-Keilani MS
title	Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy
title_short	Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy
title_full	Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy
title_fullStr	Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy
title_full_unstemmed	Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy
title_sort	pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/cb3da58ca5024fc889a488017fdcef9e
work_keys_str_mv	AT alkeilanims pramlintideanantidiabeticisantineoplasticincolorectalcancerandsynergizeswithconventionalchemotherapy AT alsmadidh pramlintideanantidiabeticisantineoplasticincolorectalcancerandsynergizeswithconventionalchemotherapy AT darweeshrs pramlintideanantidiabeticisantineoplasticincolorectalcancerandsynergizeswithconventionalchemotherapy AT alzoubikh pramlintideanantidiabeticisantineoplasticincolorectalcancerandsynergizeswithconventionalchemotherapy
_version_	1718403164133130240

Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy

Ejemplares similares